Funding for this research was provided by:
Stiftelsen Söderström Königska Sjukhemmet (SLS-759771)
Fredrik och Ingrid Thurings Stiftelse (2017-00302)
Janssen Pharmaceuticals (5-63/2015)
Received: 7 February 2020
Accepted: 30 April 2020
First Online: 13 May 2020
Ethics approval and consent to participate
: The study was approved by the regional ethical review board in Stockholm (no 2007/762–31). Consent from participants was not deemed necessary by the board due to data already being collected and available in governmental registers, as well as being fully anonymized so no specific individual could be identified.
: Not applicable.
: JR, LB, and PB are affiliated to or employees at CPE which receives grants from several entities (pharmaceutical companies, regulatory authorities, contract research organizations) for the performance of drug safety and drug utilization studies. AT, HT and JT have participated in research projects funded by Janssen and Eli Lilly with grants paid to the research institution. AD is an employee and stockholder of Janssen Inc.